3-(N-Benzyloxycarbonyl-N-ethyl)-aminopropionic acid | 136196-96-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(N-Benzyloxycarbonyl-N-ethyl)-aminopropionic acid
• 英文别名: 3-{[(Benzyloxy)carbonyl](ethyl)amino}propanoic acid；3-[ethyl(phenylmethoxycarbonyl)amino]propanoic acid
• CAS: 136196-96-8
• 化学式: C₁₃H₁₇NO₄
• 分子量: 251.282
• InChiKey: HUNCHCFZSHIKOA-UHFFFAOYSA-N

物化性质

• 沸点：
  412.4±34.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 草酰氯 、 3-(N-Benzyloxycarbonyl-N-ethyl)-aminopropionic acid 、 甲基亚硝基脲 在 氢氧化钾 、 HClO4 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 4-(N-Benzyloxycarbonyl-N-ethyl)-amino-1-hydroxybutan-2-one
  参考文献：
  名称：

  Substituted azetidinones as anti-inflammatory and antidegenerative agents

  摘要：

  已发现具有一般式(I)的新替代氮杂环丙酮，发现它们是有效的弹性蛋白酶抑制剂，因此可用作抗炎和抗退化剂。

  公开号：

  US05348953A1

文献信息

• Oxazole orexin receptor antagonists
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10435398B2

  公开（公告）日：2019-10-08

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及奥曲肽受体拮抗剂噁唑化合物。本发明还涉及本文所述噁唑化合物在潜在治疗或预防涉及奥曲肽受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在潜在预防或治疗涉及奥曲肽受体的此类疾病中的用途。
• OXAZOLE OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK SCOTT D.

  公开号：US20170320865A1

  公开（公告）日：2017-11-09

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
• US5348953A
  申请人：——

  公开号：US5348953A

  公开（公告）日：1994-09-20
• [EN] SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS
  申请人：MERCK & CO., INC.

  公开号：WO1993000332A1

  公开（公告）日：1993-01-07

  (EN) New substituted azetidinones of general formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described.(FR) Nouvelles azétidinones substituées de la formule générale (I) dont on a découvert qu'elles constituent des inhibiteurs puissants d'élastase, et par conséquent sont utiles comme agents anti-inflamatoires et antidégénératifs.
• [EN] NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS<br/>[FR] NOUVELLES AZETIDINONES A SUBSTITUTION UTILISEES COMME AGENTS ANTI-INFLAMMATOIRES ET ANTIDEGENERATIFS
  申请人：——

  公开号：WO1994013636A1

  公开（公告）日：1994-06-23

  [EN] New substituted azetidinones of general formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described.
  [FR] Nouvelles azétidinones à substitution de la formule générale (I) qui se sont révélées de puissants inhibiteurs de l'élastase et s'avèrent utiles de ce fait comme agents anti-inflammatoires et antidégénératifs.